Back to News
Market Impact: 0.32
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
Source: zacks.com
Corporate EarningsHealthcare & BiotechAnalyst Estimates
AnaptysBio reported a quarterly loss of $0.11 per share, substantially narrower than the Zacks consensus forecast for a $0.46 loss. The result also improved sharply from a $1.34-per-share loss in the prior-year quarter, indicating a $1.23 year-over-year reduction in losses.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
ANAB0.72
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- As tech swoon roils market, US inflation data on tap
- FTSE 100 today: Stocks slump as global tech rout deepens
- AI won’t pay off for the S&P 493 until CEOs rebuild the work
- Cloudflare posts its fastest growth in nearly 4 years and lifts its outlook